Legend Biotech
Somerset
New Jersey
United States
23 articles about Legend Biotech
-
Legend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) Report
3/19/2024
Legend Biotech Corporation today released its inaugural Environmental, Social & Governance (ESG) report.
-
By votes of 11-0 and 8-3, respectively, an FDA advisory committee Friday deemed the risks of early death for both Johnson & Johnson’s Carvykti and Bristol Myers Squibb’s Abecma acceptable.
-
Legend Biotech Reports Fourth Quarter and Full Year 2023 Results and Recent Highlights
3/11/2024
Legend Biotech Corporation, a global leader in cell therapy, reported its fourth quarter and full year 2023 unaudited financial results and key corporate highlights.
-
The FDA’s busy week ahead involves three decision dates for potential industry firsts and a highly anticipated advisory committee meeting for two CAR-T therapies.
-
Johnson & Johnson and Legend Biotech got a positive opinion from a European Medicines Agency panel for earlier lines of treatment, as they ready for a March FDA advisory committee meeting.
-
Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2023 Results
2/13/2024
Legend Biotech Corporation will host a conference call for investors at 8:00 am ET on Monday, March 11, 2024, to review fourth-quarter and full-year 2023 results.
-
An FDA advisory committee will meet to review J&J and Legend Biotech’s supplemental BLA for Carvykti for the treatment of relapsed or refractory multiple myeloma patients who have undergone at least one prior line of therapy.
-
Legend Biotech Announces Closing of License Transaction for Certain CAR-T Therapies Targeting DLL3
1/3/2024
Legend Biotech Corporation closed its previously announced exclusive, worldwide license agreement with Novartis Pharma AG for certain Legend Biotech chimeric antigen receptor T-cell cell therapies targeting Delta-like ligand protein 3, including Legend Biotech’s existing autologous CAR-T cell therapy candidate, LB2102.1 Under the terms of the license agreement closed , Legend Biotech will receive a $100 million upfront cash payment.
-
Legend Biotech to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
1/2/2024
Legend Biotech to Participate in the 42nd Annual J.P. Morgan Healthcare Conference.
-
As CAR T cell therapies attract significant biopharma investment, experts say there is plenty of space in the growing market for both treatments that use patients’ own cells and for those that rely on donor cells.
-
Patient-Reported Outcomes from the CARTITUDE-4 Study Showed Clinically Meaningful Improvements in Health-Related Quality of Life and Reductions in Multiple Myeloma Symptoms Following Treatment with CARVYKTI® (ciltacabtagene autoleucel)
12/12/2023
Legend Biotech Corporation, a global biotechnology company developing, manufacturing, and commercializing novel therapies to treat life-threatening diseases, announced patient-reported outcome data from the Phase 3 CARTITUDE-4 study from an oral presentation at the 2023 American Society of Hematology Annual Meeting.
-
Legend Biotech Reports Third Quarter 2023 Results and Recent Highlights
11/20/2023
Legend Biotech Corporation today reported its unaudited financial results for the three and nine months ended September 30, 2023 and key corporate highlights.
-
After success with J&J, Legend strikes another license agreement, this one with Swiss pharma Novartis around CAR-T therapies.
-
Legend Biotech Announces Exclusive, Global License Agreement for Certain CAR-T Therapies Targeting DLL3
11/13/2023
Legend Biotech Corporation announced today that Legend Biotech Ireland Limited, a wholly owned subsidiary of Legend Biotech, has entered into an exclusive, global license agreement (License Agreement) with Novartis Pharma AG for certain Legend Biotech chimeric antigen receptor T-cell (CAR-T) cell therapies targeting DLL3, including its autologous CAR-T cell therapy candidate, LB2102 (NCT05680922).
-
The leaked data show that Carvykti cuts the risk of disease relapse by 74% versus standard chemotherapy regimens.
-
Legend Biotech and J&J, Adicet Bio, Curis and Immutep present optimistic early and mid-stage results at ASCO.
-
The U.S. SEC continues to tighten the screws on Chinese companies, adding more than 80 companies to its expanding list of companies that might be dropped from U.S. stock exchanges.
-
CARVYKTI™ (ciltacabtagene autoleucel), BCMA-Directed CAR-T Therapy, Receives U.S. FDA Approval for the Treatment of Adult Patients With Relapsed or Refractory Multiple Myeloma
3/1/2022
Legend Biotech Corporation announced that the U.S. Food and Drug Administration has approved its first product, CARVYKTI™, for the treatment of adults with relapsed or refractory multiple myeloma who have received four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
-
Clinical Catch-Up: December 11-17
12/20/2021
It was an enormously busy week with plenty of announcements from the American Society of Hematology meeting and numerous companies working to get the news out ahead of the holidays and year-end. Here’s a look. -
The U.S. Food and Drug Administration has a very busy calendar for the end of November and beginning of December. Here’s a look.